抗病毒药物研发方法。
Approaches to antiviral drug development.
作者信息
Prusoff W H, Lin T S, August E M, Wood T G, Marongiu M E
机构信息
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510.
出版信息
Yale J Biol Med. 1989 Mar-Apr;62(2):215-25.
At present, only a few drugs have been approved by the FDA for therapy of viral infections in humans. There is a great need for antiviral drugs with increased potency and decreased toxicity, as well as drugs to treat viral diseases for which no drug or vaccine is currently available. Two approaches for development of antiviral drugs are described--an empirical strategy and a rational strategy--with several examples of each. Although many compounds have potent antiviral activity in cell culture, only a small fraction of these will go on to become antiviral drugs for use in humans. At this time, only seven synthetic compounds and alpha interferon have been approved by the FDA for therapy of viral infections in humans. None of these approved drugs are without toxicities, however, and hence there is a great need for antiviral drugs with increased potency and decreased toxicity, as well as for drugs to treat viral diseases for which no drug or vaccine is currently available. Two approaches for the development of antiviral drugs--the empirical and the rational strategies--and their applications and future directions are discussed.
目前，美国食品药品监督管理局（FDA）仅批准了少数几种药物用于治疗人类病毒感染。迫切需要开发效力更强、毒性更低的抗病毒药物，以及用于治疗目前尚无药物或疫苗的病毒性疾病的药物。本文描述了两种开发抗病毒药物的方法——经验性策略和理性策略——并分别给出了几个例子。尽管许多化合物在细胞培养中具有强大的抗病毒活性，但其中只有一小部分会最终成为用于人类的抗病毒药物。目前，FDA仅批准了七种合成化合物和α干扰素用于治疗人类病毒感染。然而，这些获批药物都存在毒性，因此迫切需要效力更强、毒性更低的抗病毒药物，以及用于治疗目前尚无药物或疫苗的病毒性疾病的药物。本文讨论了开发抗病毒药物的两种方法——经验性策略和理性策略——及其应用和未来发展方向。
Zotero 插件